SS Innovations International, Inc. reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing substantial growth in its surgical robotics business. The company, which develops affordable robotic surgery technologies, filed its Annual Report on Form 10-K with the Securities and Exchange Commission on March 10, 2026. Fourth quarter revenue increased 79.1% to $14.5 million from $8.1 million in the same period of 2024, while full year revenue grew 105.7% to $42.5 million from $20.6 million in 2024. Gross profit rose 131.2% for the full year to $19.5 million, though the company reported a net loss of $12.1 million for 2025, an improvement from the $19.2 million loss in 2024.
The SSi Mantra surgical robotic system installations showed particularly strong growth, with 40 installations in the fourth quarter representing an 81.8% increase from the same period in 2024. Full year installations totaled 103, up 119.1% from 47 installations in 2024. As of December 31, 2025, the cumulative installed base reached 168 systems across ten countries, with 7,885 cumulative surgeries performed including 120 telesurgeries, 390 cardiac procedures and 121 pediatric surgeries. Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, highlighted the company's market expansion achievements. "We gained significant share of the surgical robotics market in India, expanded into new global geographies, and progressed along the regulatory pathways required for entering the United States and European Union markets," he stated.
The company submitted a 510(k) premarket notification to the U.S. Food and Drug Administration on December 5, 2025, covering multiple surgical indications, and anticipates FDA review completion by mid-2026. The company also continues working toward European Union CE marking certification for the SSi Mantra, which it believes could be obtained in 2026. These regulatory milestones represent critical steps toward entering two of the world's largest medical device markets, potentially expanding access to the company's cost-effective robotic surgery solutions. Following the quarter end, SS Innovations completed a private placement generating approximately $18.6 million in gross proceeds to support growth initiatives. The financing included participation from company directors and executive officers as well as new institutional investors.
Dr. Srivastava noted this funding would "fuel SS Innovations' growth in 2026 and beyond" as the company invests in system enhancements and market expansion. Technological advancements featured prominently in the company's 2025 achievements. On November 6, 2025, SS Innovations announced the first telesurgery performed with its SSi Mantra Tele Surgeon Console. Subsequent developments included five new 5-millimeter surgical instruments announced on January 6, 2026, designed for pediatric, cardiac, and head and neck surgery procedures involving smaller anatomical structures. The company's progress in telesurgery represents a significant development in remote surgical capabilities, potentially increasing access to specialized surgical expertise in underserved regions. With zero long-term debt and $3.2 million in cash and cash equivalents as of December 31, 2025, excluding restricted cash, SS Innovations appears positioned to continue its expansion while pursuing regulatory approvals in key markets.
